NeuroOne Medical Technologies announced the successful completion of three large-animal procedures using its next-generation StereoCED™ platform. The procedures validated the platform's ability to perform robotic-assisted drug delivery and, in a claimed industry first, simultaneously record electrophysiological activity from the same targeted brain tissue.
Key Details
- Event: Successfully completed three preclinical procedures in large animals at the University of Minnesota, demonstrating technical feasibility.
- Technology Milestone: The StereoCED™ platform delivered a study agent and recorded intracranial electrophysiological activity from the same region, a combination the company believes has not been previously demonstrated.
- Next Steps & Financials: The results support a planned launch for human investigational clinical studies later in the current quarter. The company expects to recognize initial revenue from the research program in fiscal Q4 2026.